Salvage Post-Operative Stereotatic Ablative Radiotherapy for Re-Current Squamous Cell Carcinoma of Head and Neck
Open Access
Abstract
Background and Objectives: Patients with recurrent squamous cell carcinoma of the head and neck (rHNC) face an aggressive disease. Surgical resection is the gold standard treatment. Immediate adjuvant post-operative stereotactic ablative radiotherapy (PO-SABR) for rHNC is debatable. Materials and Methods: We retrospectively identified patients who were treated with PO-SABR at the AC Camargo Cancer Center, Brazil. Results: Eleven patients were treated between 2018 and 2021. The median time between salvage surgery and PO-SABR was 31 days (range, 25–42) and the median PO-SABR total dose was 40 Gy (range, 30–48 Gy). The 2-and 4-year actuarial DFS were 62.3% and 41.6%, while the 2-and 4-year OS probabilities were 80.0% and 53.3%, respectively. Eight (72.7%) patients were alive and six (54.5%) were without disease at the last follow-up. Two (18.1%) patients had local failure in the PO-SABR field. Three (27.3%) patients had distant metastasis, diagnosed in a median time of 9 months (range, 4–13) after completion of PO-SABR. On univariate analysis, predictive factors related to worse OS were: interval between previous radiotherapy and PO-SABR ≤ 24 months (p = 0.033) and location of the salvage target in the oral cavity (p = 0.013). The total dose of PO-SABR given in more than three fractions was marginally statistically significant, favoring the OS (p = 0.051). Conclusions: Our results encourage the use of a more aggressive approach in selected patients with rHNC by combining salvage surgery with immediate PO-SABRT, but this association needs to be further explored.Keywords
Funding Information
- AC Camargo Cancer Center
This publication has 25 references indexed in Scilit:
- Practical Considerations in the Re-Irradiation of Recurrent and Second Primary Head-and-Neck Cancer: Who, Why, How, and How Much?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Salvage Reirradiaton With Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck TumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- ACR Appropriateness Criteria® Retreatment of Recurrent Head and Neck Cancer After Prior Definitive RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- CyberKnife Stereotactic Radiosurgery for Recurrent Squamous Cell Carcinoma of the Head and Neck Following Salvage Surgery with Close or Positive MarginsThe Laryngoscope, 2010
- Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Long-term outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapyEuropean Archives of Oto-Rhino-Laryngology, 2009
- Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck RegionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Local Surgical, Ablative, and Radiation Treatment of MetastasesCA: A Cancer Journal for Clinicians, 2009
- Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911Journal of Clinical Oncology, 2007
- Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neckHead & Neck, 2007